DOCSLIB.ORG

Colistin Combinations Veterinary Medicinal Products Were Identified with Colistin Doses of Below 50,000 IU Per Kg Body Weight

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Colistin Combinations Veterinary Medicinal Products Were Identified with Colistin Doses of Below 50,000 IU Per Kg Body Weight Annex I List of the names, pharmaceutical forms, strengths of the veterinary medicinal products, animal species, route of administration, and marketing authorisation holders in the Member States Member Marketing Name INN Strength Pharmaceutical Animal Route of State authorisation form species administration EU/EEA holder Bulgaria Farma vet Ltd. Колитетравит / Oxytetracycline 5.0 g Oral solution Chickens and Oral 40 Otec Paisii str. COLI – TETRAVIT hydrochloride pigs administration Shumen Colistin sulphate 3 500 000 Bulgaria UI Bulgaria COOPHAVET S.A.S. Колисултрикс/ Trimethoprim 3.75 g Oral powder Chickens, Oral administration B.P. 7 Saint Herblon COLISULTRIX Colistin sulphate 50 MIU rabbits, pigs, 44153 ANCENIS calves and Cedex lambs France Croatia Arnika Veterina COLISULTRIX Trimethoprim 3.75 g Oral powder Calves, lambs, Oral d.o.o. Colistin sulphate 50 MIU kids, piglets, Vodovodna 20a poultry and 10000 Zagreb rabbits Croatia Croatia Ceva Santé Animale QUINOCOL Enrofloxacin 100 g Oral solution Chicken, Oral 10 Avenue de la Colistin sulphate 41.67 g turkey Ballastière 33500 Libourne France Cyprus FATRO S.p.A. BACOLAM powder Amoxicillin trihydrate 100 mg Powder for oral Calves, sheep, Administer the Via Emilia, 285 for oral solution for Colistin sulphate 500,000 solution goats, pigs, dose subdivided 40064 Ozzano Emilia calves, sheep, I.U. foals, into two (Bologna) goats, pigs, foals, chickens, administrations Italy chickens, turkeys turkeys each day, (excluding layers) (excluding dissolved in layers) drinking water or in milk. 2/24 Member Marketing Name INN Strength Pharmaceutical Animal Route of State authorisation form species administration EU/EEA holder Cyprus Vetoquinol Italia ZEMAMIX premix for Amoxicillin trihydrate 11.48 g Premix for Pigs Premix for S.R.L medicated Colistin sulphate 4.00 g medicated medicated Via Piana, 265 feedingstuff for pigs feedingstuff feedingstuff in 47032 Bertinoro insoluble powder, Italy to be administered orally properly mixed in solid feed. Czech LAVET AMOXYCOL plv.sol. Amoxicillin trihydrate 640 mg/g Powder for oral Pigs, chicken Oral Republic Pharmaceuticals Ltd. Colistin sulphate 3 200 000 solution for use in (broilers) Ottó u.14 IU/g drinking water or 1161 Budapest in feed Hungary Czech COOPHAVET S.A.S. BELCOSPIRA ORAL Colistin sulphate 500 000 Powder for oral Calves, Oral Republic B.P. 7 Saint Herblon prášek pro přípravu Spiramycin adipate IU solution piglets, foals, 44153 ANCENIS perorálního roztoku 650 000 chicken Cedex IU France Czech COOPHAVET S.A.S. COLISULTRIX plv. Trimethoprim 37.5 mg Powder for oral Chicken Oral Republic B.P. 7 Saint Herblon sol. Colistin sulphate 500 000 solution 44153 ANCENIS IU/g Cedex France 3/24 Member Marketing Name INN Strength Pharmaceutical Animal Route of State authorisation form species administration EU/EEA holder Czech Industria Italiana MICROAMOX COLI Amoxicillin trihydrate 100 mg/g Premix for Pigs Oral Republic Integratori Trei premix pro medikaci Colistin sulphate 600 000 medicated feed S.p.A. krmiva IU/g Via Corassori, 62 41100 Modena Italy France MERIAL BELCOSPIRA ORAL Colistin sulphate 500 000 Powder for oral Cattle, pigs, Oral use 29 avenue Tony IU/g use poultry Garnier Spiramycin adipate 650 000 69007 LYON IU/g France France LABORATOIRES COLAMPI B Ampicillin trihydrate 25 mg/g Powder for oral Pigs, calves Oral use BIOVE Colistin sulphate 0.075 use 3 Rue de Lorraine MIU/g 62510 Arques France France LABORATOIRES COLAMPI O Ampicillin trihydrate 1 g/tablet Tablet Calves Oral use BIOVE Colistin sulphate 1 MIU/ 3 Rue de Lorraine tablet 62510 Arques France France VETOQUINOL COLIDIARYL Colistin sulphate 83 400 Powder for oral Lamb, goat, Oral use Magny Vernois Erythromycin estolate IU/g use piglets, foals, 70200 Lure 16 600 calves France IU/g 4/24 Member Marketing Name INN Strength Pharmaceutical Animal Route of State authorisation form species administration EU/EEA holder France MERIAL COLISULTRIX Colistin sulphate 500 000 Powder for oral Lamb, goat, Oral use 29 avenue Tony POUDRE IU/g use rabbits, pigs, Garnier Trimethoprim 37.5 mg/g calves, poultry 69007 LYON France France VIRBAC ENTEROGEL 30 Colistin sulphate 10.5 MIU/ Oral paste Foals, calves Oral use 1ere Avenue 2065m syringe L.I.D. Scopolamine 0.216 g/ 06516 Carros Cedex syringe France Sulfaguanidine 4.2 g/ syringe France VIRBAC INTESTIVO Colistin sulphate 2.5 MIU/ Tablet Lamb, goat, Oral use 1ere Avenue 2065m tablet calve L.I.D. Sulfaguanidine 1 g/tablet 06516 Carros Cedex France France MERIAL N.P. 8 Colistin sulphate 300 000 Powder for oral Lamb, goat, Oral use 29 avenue Tony IU/g use rabbits, pigs, Garnier Neomycin sulfate 60 000 calves, poultry 69007 LYON IU/g France France QALIAN OXYCOLI Colistin sulphate 200 000 Premix for Pigs, calves Oral use 34 rue Jean Monnet IU/g medicated feed ZI D’Etiché Oxytetracycline 0.07 g/g BP20341 hydrochloride 49503 Segré Cedex France 5/24 Member Marketing Name INN Strength Pharmaceutical Animal Route of State authorisation form species administration EU/EEA holder France Ceva Santé Animale PHADILACT Ampicillin trihydrate 5.00 mg/g Powder for oral Lamb, goat, Oral use 10 Avenue de la Colistin sulphate 1 000 000 use calves, poultry Ballastière IU/g 33500 Libourne France France QALIAN PREMELANGE Colistin sulphate 700 000 Premix Lamb, calves Oral use 34 rue Jean Monnet MEDICAMENTEUX IU/g ZI D’Etiché CS FRANVET Sulfadimethoxine 210 mg/g BP20341 49503 Segré Cedex France France VETOQUINOL SEPTOTRYL- Colistin sulphate 2 MIU/ Tablet Lamb, dogs, Oral use Magny Vernois COLISTINE tablet foals, calves 70200 Lure Sulfamethoxypyridazine 1 g/tablet France Hungary Lavet Amoxycol por Amoxicillin trihydrate 640.0 Powder for oral Pigs, chickens In drinking water Gyógyszergyártó Kft. belsőleges oldathoz mg/g solution use Ottó u. 14 A.U.V. Colistin sulphate 133.3 1161 Budapest mg/g Hungary Hungary Industria Italiana BETAMICYN Amoxicillin trihydrate 100 g/kg Premix for Pigs In feed use Integratori Trei gyógypremix Colistin sulphate 600 medicated S.p.A. sertések részére MIU/kg feeding stuff Viale Corassori, 62 A.U.V. 41100 Modena Italy 6/24 Member Marketing Name INN Strength Pharmaceutical Animal Route of State authorisation form species administration EU/EEA holder Hungary Rhone Vet Kft. Colisutrix belsőleges Trimethoprim 3.75 Powder for oral Cattle In drinking water Petőfi u. 9. por g/100 g solution (calves), use 2053 Herceghalom Colistin sulphate 50 sheep Hungary MIU/100 g (lambs), pigs and chickens, rabbit, goat Italy Fatro S.p.a. COMBOMIX Amoxicillin trihydrate 115 mg/g Premix for Pigs, chickens Oral Via Emilia, 285 Colistin sulphate 40 mg/g medicated (other than 40064 Ozzano Emilia feeding stuff laying hens in Italy lay) Italy Industria Italiana BETAMICYN Amoxicillin trihydrate 100 g/kg Premix for Pigs Oral Integratori Trei Colistin sulphate 600 medicated S.P.A. MIU/kg feeding stuff Via Affarosa, 4 42010 - Rio Saliceto Italy Italy Doxal Italia S.p.a. CLOVER BMP Amoxicillin trihydrate 115 g/kg Premix for Pigs Oral largo Donegani 2 Colistin sulphate 40 g/kg medicated 20121 - Milano feeding stuff Italy Italy Industria Italiana DUOBAN Doxycycline hyclate 60 mg/g Premix for Pigs, rabbits Oral Integratori Trei Colistin sulphate 1 200 000 medicated S.P.A. UI/g feeding stuff Via Affarosa, 4 42010 - Rio Saliceto Italy 7/24 Member Marketing Name INN Strength Pharmaceutical Animal Route of State authorisation form species administration EU/EEA holder Italy Virbac S.r.l. DUALMIX Amoxicillin trihydrate 115 mg/g Premix for Pigs, chickens Oral Via Caldera 21 Colistin sulphate 4 mg/g medicated (except hens 20153 Milano (20 000 feeding stuff producing Italy UI/mg) eggs for human consumption) Italy Fatro S.p.a. BACOLAM Amoxicillin trihydrate 500 mg/g Powder for oral Calves, sheep Oral Via Emilia, 285 Colistin sulphate 2 500 000 solution and goats, 40064 Ozzano Emilia IU/g pigs, ponies, Italy chickens, turkeys (excluding hens) Italy Intervet Productions NADASIN Amoxicillin trihydrate 500 mg/g Oral powder for Calves, pigs, Oral S.r.l. Colistin sulphate 200 mg/g use in drinking chickens Via Nettunense, km water or liquid (other than 20,300 feed laying hens), 04011 - Aprilia turkeys Italy Italy Vetoquinol Italia NEOMIX COMPLEX Neomycin sulfate 200 mg/g Oral powder, for Calves, Oral S.r.l. Colistin sulphate 20 000 use in drinking piglets, Via Piana, 265 IU/g water or liquid broilers and 47032 Bertinoro feed turkeys Italy Italy Vétoquinol Italia ZEMAMIX Amoxicillin trihydrate 100 mg/g Oral powder Pigs Oral use S.r.l. Colistin sulphate 40 mg/g Via Piana 265 47032 Bertinoro Italy 8/24 Member Marketing Name INN Strength Pharmaceutical Animal Route of State authorisation form species administration EU/EEA holder Italy Virbac S.r.l. STABOX COLI Amoxicillin trihydrate 100 mg/g Premix for Pigs, chickens Oral Via Caldera 21 Colistin sulphate 800 000 medicated (except hens 20153 Milano IU/g feeding producing Italy eggs for human consumption) Latvia Ceva Santé Animale Quinocol Oral Enrofloxacin 100 g Solution for oral Chicken, Oral use 10 Avenue de la Solution Colistin sulphate 41.67 g use turkeys Ballastière 33500 Libourne France Lithuania Lavet AMOXYCOL, Amoxicillin trihydrate 640 Water soluble oral Pig, chicken Oral Pharmaceuticals Ltd. geriamieji milteliai mg/ml solution Ottó u. 14. Colistin sulphate 3 200 000 H-1161 Budapest IU/ml Hungary Lithuania COOPHAVET S.A.S. COLISULTRIX, Trimethoprim 3.75 Oral powder Calves, lamb, Oral B.P. 7 Saint Herblon geriamieji milteliai g/100 g kid, piglets, 44153 ANCENIS Colistin sulphate 50 poultry and Cedex MIU/100 g rabbits France Lithuania COOPHAVET S.A.S.
Load more

Recommended publications
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Polymyxin B & Colistin Dosing Tip Sheet
    Stanford Antimicrobial Safety & Sustainability Program Polymyxin B & Colistin Dosing Tip Sheet What: Polymyxin B is preferred over Colistin (polymyxin E) for infections due to multidrug resistant gram- negative bacilli at Stanford Health Care. SHC formulary restriction criteria – Polymyxin B 1. Infectious Disease Consultation and ID recommendation for use 2. Cystic Fibrosis team SHC formulary restriction criteria – Colistin 1. Treatment of urinary tract infections 2. Inhalation route Why: Polymyxin B and Colistin have the same spectrum of activity. However, Polymyxin B has favorable clinical pharmacologic properties compared to Colistin o Polymyxin B is an active drug, whereas Colistin is administered as the prodrug colistimethate sodium (CMS) and has variable and slow (hours) conversion to the active moiety o Polymyxin B may be less nephrotoxic How: Polymyxin B and Colistin dosing is NOT interchangeable o Polymyxin B is usually dosed by “unit”, not “mg” o Note that with Polymyxin B, each 500,000 units is diluted in 300-500mL: a typical dose may result in 1L of fluid o Consult ID pharmacists if MIC ≥ 2 for alternative dosing strategies Dosing 50-79 30-49 10-29 IHD Route ≥80 mL/min mL/min mL/min mL/min CRRT Polymyxin B No Data; Use actual body IV 7,500 – 12,500 units/kg Q12H Consult ID weight; adjusted body wt for obese pharmacist 2.5 mg/kg 1.5 mg/kg 5 mg/kg/day 1.25–1.9 mg/kg Q24H 1.5 mg/kg Q24-48h Colistin IV in 2-3 divided -OR- Use ideal body Q12H Q36H 2.5 mg/kg weight doses 1.25 mg/kg Q12h Q12-24H Doses expressed in colistin base activity Inhalation 150 mg inhalation Q12H Conversions: Colistimethate sodium 1 mg = ~12,500 units of colistimethate sodium Colistimethate sodium ~2.67 mg = 1 mg of colistin base activity 1 mg colistin base activity (CBA) = 30,000 IU colistin 1 mg polymyxin B = 10,000 IU polymyxin B Orig date: 2/23/2015 LM, EM Stanford Antimicrobial Safety & Sustainability Program References: Micromedex online, accessed 2/17/2016 Nelson, Brian C., et al.
    [Show full text]
  • Fosfomycin Activity Versus Carbapenem-Resistant Enterobacteriaceae and Vancomycin-Resistant Enterococcus, Detroit, 2008–10
    The Journal of Antibiotics (2013) 66, 625–627 & 2013 Japan Antibiotics Research Association All rights reserved 0021-8820/13 www.nature.com/ja NOTE Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008–10 Jason M Pogue1,2, Dror Marchaim2,3,4, Odaliz Abreu-Lanfranco2, Bharath Sunkara2, Ryan P Mynatt1, Jing J Zhao1, Suchitha Bheemreddy2, Kayoko Hayakawa2, Emily T Martin1, Sorabh Dhar2, Keith S Kaye2 and Paul R Lephart5 The Journal of Antibiotics (2013) 66, 625–627; doi:10.1038/ja.2013.56; published online 29 May 2013 Keywords: CRE; HAI; multidrug resistant; UTI; VRE; in-vitro Enterobacteriaceae and enterococci are among the most common culture coupled with potential clinical signs of infection such as causes of urinary tract infections (UTI) in adults.1 Carbapenem- mental status changes. In these scenarios, when CRE or VRE are the resistant Enterobacteriaceae (CRE) and vancomycin-resistant offending pathogens, often in elderly incontinent institutionalized Enterococcus (VRE) are multidrug-resistant (MDR) pathogens, individuals,12,13 patients are hospitalized and treated with intravenous which have become endemic in many locations worldwide.2,3 These (IV) broad-spectrum and sometime toxic agents, owing to lack of oral pathogens are associated with devastating outcomes among patients regimens. If these patients could have been managed in the outpatient and their continued dissemination and spread pose a threat to public settings, both the patients and the acute-care facilities
    [Show full text]
  • Management of Carbapenem-Resistant Enterobacteriaceae Infections
    Clinical Microbiology and Infection xxx (xxxx) xxx Contents lists available at ScienceDirect Clinical Microbiology and Infection journal homepage: www.clinicalmicrobiologyandinfection.com Review Management of carbapenem-resistant Enterobacteriaceae infections * E. Durante-Mangoni , R. Andini, R. Zampino Internal Medicine, University of Campania ‘L. Vanvitelli’ & Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy article info abstract Article history: Background: Carbapenem resistance is defined as in vitro non-susceptibility to any carbapenem and/or Received 2 October 2018 documented production of a carbapenemase. This feature has rapidly spread worldwide among clinical Received in revised form isolates of Enterobacteriaceae, mostly Klebsiella spp., and is associated with diverse molecular mecha- 7 April 2019 nisms. Carbapenem resistance is often associated with resistance to all traditional b-lactams and other Accepted 10 April 2019 classes of antibiotics, denoting a typical example of an extensively drug-resistant phenotype. Available online xxx Objectives: To summarize and interpret in a balanced manner the most clinically relevant data in terms Editor: M. Paul of carbapenem-resistant Enterobacteriaceae (CRE) infection management. Sources: Data were extracted by PubMed and clinicaltrials.gov search and manual scrutiny among ref- Keywords: erences of analysed articles. Ceftazidime-avibactam Content: Features of newer and older, rediscovered antimicrobial options for CRE are described. Obser- Clinical failure vational studies and randomized clinical trials (RCT) of CRE treatment are summarized, with a specific Colistin focus on the effects of monotherapy compared with combination treatment. Ertapenem Implications: The available evidence on the current management of CRE mostly comes from observa- Extensively drug-resistant tional, non-comparative, retrospective, small studies, with a high risk of selection bias.
    [Show full text]
  • Polymyxin B* Class: Polymyxins Overview Polymyxin B Is a Polypeptide Bactericidal Antibiotic. the Polymyxins Were Discovered In
    Polymyxin B* Class: Polymyxins Overview Polymyxin B is a polypeptide bactericidal antibiotic. The polymyxins were discovered in 1947 and introduced to the medical community in the 1950s. Colistin, also called polymyxin E and its parenteral form, colistimethate, are related polymyxins. Polymyxins can be administered orally, topically or parenterally, including intrathecally and intraperitoneally. However parenteral administration is primarily used in life threatening infections caused by Gram-negative bacilli or Pseudomonas species that are resistant to other drugs. Polymyxins exert their effect on the bacterial cell membrane by affecting phospholipids and interfering with membrane function and permeability, which results in cell death. Polymyxins are more effective against Gram-negative than Gram- positive bacteria and are effective against all Gram-negative bacteria except Proteus species. These antibiotics act synergistically with potentiated sulfonamides, tetracyclines and certain other antimicrobials. Polymyxins also limit activity of endotoxins in body fluids and therefore, may be beneficial in therapy for endotoxemia. Polymyxins are not well absorbed into the blood after either oral or topical administration. Polymyxins bind to cell membranes, purulent exudates and tissue debris. The drugs are eliminated from the kidneys with approximately sixty percent of polymyxin B and ninety percent of colistin excreted unchanged. Polymyxins are considered nephrotoxic and neurotoxic and neuromuscular blockade is seen at higher concentrations. In reality, the potential for nephrotoxicity is minimal when the drugs are utilized properly, especially colistin. Polymyxin B is a potent releaser of histamines and hypersensitivity reactions can occur. Parenteral polymyxins are often characterized by intense pain at the injection site. Divalent cations, unsaturated fatty acids and quaternary ammonium compounds inhibit the activity of polymyxins.
    [Show full text]
  • Third ESVAC Report
    Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011 Third ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role Guiding principles The European Medicines Agency is the European Union • We are strongly committed to public and animal (EU) body responsible for coordinating the existing health. scientific resources put at its disposal by Member States • We make independent recommendations based on for the evaluation, supervision and pharmacovigilance scientific evidence, using state-of-the-art knowledge of medicinal products. and expertise in our field. • We support research and innovation to stimulate the The Agency provides the Member States and the development of better medicines. institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, • We value the contribution of our partners and stake- safety and efficacy of medicinal products for human or holders to our work. veterinary use referred to it in accordance with the • We assure continual improvement of our processes provisions of EU legislation relating to medicinal prod- and procedures, in accordance with recognised quality ucts. standards. • We adhere to high standards of professional and Principal activities personal integrity. Working with the Member States and the European • We communicate in an open, transparent manner Commission as partners in a European medicines with all of our partners, stakeholders and colleagues. network, the European Medicines Agency: • We promote the well-being, motivation and ongoing professional development of every member of the • provides independent, science-based recommenda- Agency.
    [Show full text]
  • Antimicrobials As Single and Combination Therapy for Colistin-Resistant Pseudomonas Aeruginosa at a University Hospital in Thailand
    antibiotics Article Antimicrobials as Single and Combination Therapy for Colistin-Resistant Pseudomonas aeruginosa at a University Hospital in Thailand Supanun Pungcharoenkijkul 1,2, Jantima Traipattanakul 3, Sudaluck Thunyaharn 4 and Wichai Santimaleeworagun 5,6,* 1 College of Pharmacotherapy Thailand, Nontaburi 11000, Thailand; [email protected] 2 Department of Pharmacist, Nopparat Rajathanee Hospital, Bangkok 10230, Thailand 3 Division of Infectious Disease, Department of Medicine, Phramongkutklao Hospital, Bangkok 10400, Thailand; [email protected] 4 Faculty of Medical Technology, Nakhonratchasima College, Nakhon Ratchasima 30000, Thailand; [email protected] 5 Department of Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakorn Pathom 73000, Thailand 6 Pharmaceutical Initiative for Resistant Bacteria and Infectious Disease Working Group (PIRBIG), Nakorn Pathom 73000, Thailand * Correspondence: [email protected]; Tel.: +66-3425-580-0 Received: 29 June 2020; Accepted: 31 July 2020; Published: 3 August 2020 Abstract: Global infections with colistin-resistant Pseudomonas aeruginosa (CoR-PA) are increasing; there are currently very few studies focused on the antimicrobial susceptibility of CoR-PA isolates, and none from Thailand. Here, we investigated the impact of various antimicrobials, alone and in combination, via the in vitro testing of CoR-PA clinical isolates. Eighteen CoR-PA isolates were obtained from patients treated at Phramongkutklao Hospital from January 2010 through June 2019; these were classified into six different clonal types by using the enterobacterial repetitive intergenic consensus (ERIC)-PCR method, with a high prevalence of Group A (27.8%). The antimicrobial susceptibility was determined as the minimal inhibitory concentrations (MICs) using the epsilometer-test (E-test) method. The synergistic activities of six antimicrobial combinations were reported via the fractional-inhibitory-concentration index.
    [Show full text]
  • The Effect of Colistin Treatment on the Selection of Colistin-Resistant Escherichia Coli in Weaner Pigs
    antibiotics Article The Effect of Colistin Treatment on the Selection of Colistin-Resistant Escherichia coli in Weaner Pigs Shahana Ahmed 1, Claus Hansen 2 , Ane Laursen Dahlkilde 1, Ana Herrero-Fresno 1, Ken Steen Pedersen 1, Jens Peter Nielsen 1 and John Elmerdahl Olsen 1,* 1 Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 1870 Frederiksberg C, Denmark; [email protected] (S.A.); [email protected] (A.L.D.); [email protected] (A.H.-F.); [email protected] (K.S.P.); [email protected] (J.P.N.) 2 Danish Agriculture & Food Council, SEGES Pig Research Centre, 1609 Copenhagen V, Denmark; [email protected] * Correspondence: [email protected]; Tel.: +45-35-33-27-84 Abstract: The treatment of diarrhea in the postweaning period is a common reason for the use of antimicrobials in pig production, and Escherichia coli is the single most important causative agent for this condition. Colistin has recently been classified as a critically important antimicrobial for human health, as it is a last-resort drug against certain multi-drug-resistant Gram-negative bacteria. Therefore, the use of colistin has been significantly reduced in some countries, including Denmark. Despite this, the drug is still commonly used to treat diarrhea in pigs in many countries, and there is a need to understand the risks associated with this practice. We performed a prospective cohort study to investigate the effect of colistin treatment on the changes in the average minimum inhibitory concentration (MIC) in commensal E. coli in a pig herd where no colistin-resistant bacteria were Citation: Ahmed, S.; Hansen, C.; detectable before treatment.
    [Show full text]
  • Colistin (Polymyxin E Or Colistimethate)
    ColistinColistin (Polymyxin (Polymyxin E or Colistimethate) E or Colistimethate) IV Only Use requires formal ID Consult Colistin (also known as Polymyxin E or Colistimethate) and Polymyxin B are the two different polymyxin antibiotics. Colistin is a prodrug (Colistimethate sodium). The product vials may be labeled as International Units (IU) of prodrug, or mg of the active product: colistin base activity (CBA). To avoid major dosing errors, carefully read vial labels. Recommend that all doses be converted to mg of CBA. Conversion: 1,000,000 units of Colistimethate (prodrug) = 80 mg of Colistimethate (prodrug) = 30 mg of colistin base activity (CBA) Activity: Coverage against most gram-negatives, including many multi-drug resistant (MDR) Enterobacteriaceae (such as E. coli, Klebsiella spp.; including ESBL-producing and carbapenem-resistant Enterobacteriaceae), Pseudomonas spp., and Acinetobacter spp. NOT ACTIVE against Proteus spp., Serratia spp., Providencia spp, Burkholderia spp, Stenotrophomonas spp, gram-negative cocci, gram-positive organisms, or anaerobes Criteria for Use: Treatment of infections due to MDR Enterobacteriaceae, Pseudomonas spp., and Acinetobacter spp. with no other treatment options Treatment of UTI. Colistin preferred over polymyxin B for UTIs Unacceptable Uses: Empiric treatment of suspected gram-negative infections Use as monotherapy due to rapid resistance development Dosing in Adults: Optimal dosing regimens are not well established Standard dose: 5 mg CBA/kg ONCE (load), then 2.5 mg CBA/kg Q12H Renal dose
    [Show full text]
  • Cefalexin (Ceporex) 500Mg Capsules: Each Capsule Contains 500Mg Cefalexin
    Cefalexin Ceporex Oral Preparations PRODUCT DESCRIPTION Cefalexin (Ceporex) 500mg Capsules: Each capsule contains 500mg Cefalexin. The capsule is Size #0 hard gelatine capsule with an opaque caramel coloured body printed with GS 3ZI axially in white ink and a plain opaque dark grey cap containing white to yellowish white powder. It contains Magnesium stearate as an excipient. Cefalexin (Ceporex) 125mg/5mL Powder for Suspension: Each 5 ml of constituted suspension contains 125 mg of cefalexin. Excipients include Sodium calcium edetate, Acacia, Orange Bramble Flavour SO 370, Polvaromas, Citric Acid BP anhydrous 100-Mesh, Sodium citrate anhydrous, Sunset Yellow Ariavit, Caster sugar, Icing sugar. The powder prior to reconstitution has a pale pink coarse powder with characteristic odour. Cefalexin (Ceporex) 250mg/5mL Powder for Suspension: Each 5 ml of constituted suspension contains 250 mg of cefalexin. Excipients include Sodium calcium edetate, Acacia, Orange Bramble Flavour SO 370, Polvaromas, Citric Acid BP anhydrous 100-Mesh, Sodium citrate anhydrous, Sunset Yellow Ariavit, Caster sugar, Icing sugar. The powder prior to reconstitution has a pale pink coarse powder with characteristic odour. Cefalexin (Ceporex) Powder for Suspension (Oral Drops): Each 1 ml of constituted drops contains 100 mg of cefalexin. Excipients include Sodium calcium edetate, Acacia, Orange Bramble Flavour SO 370, Polvaromas, Citric Acid BP anhydrous 100-Mesh, Sodium citrate anhydrous, Sunset Yellow Ariavit, Caster sugar. The powder prior to reconstitution gives a pale pink to orange granules with a characteristic odour. PHARMACOLOGICAL PROPERTIES Mechanism of Action Cefalexin is an oral broad- spectrum antibiotic. In adequate concentrations it is bactericidal for sensitive proliferating microorganisms by inhibiting the biosynthesis of the cell wall.
    [Show full text]
  • Colistin and Polymyxin B in Critical Care Argyris Michalopoulos, MD, FCCP, Fccma, Matthew E
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Qazvin University of Medical Sciences Repository Crit Care Clin 24 (2008) 377–391 Colistin and Polymyxin B in Critical Care Argyris Michalopoulos, MD, FCCP, FCCMa, Matthew E. Falagas, MD, MSc, DScb,c,* aIntensive Care Unit, Henry Dunant Hospital, 107 Mesogeion Avenue, 11526, Athens, Greece bTufts University School of Medicine, 145 Harrison Avenue, Boston, MA 02111, USA cAlfa Institute of Biomedical Sciences, 9 Neapoleos Street, 11523, Athens, Greece During the last years, the emergence of gram-negative bacteria resis- tant to most available antibiotics all over the world has led to the read- ministration of polymyxins B and E as ‘‘salvage’’ therapy in critically ill patients [1]. The incidence of intensive care unit (ICU)–acquired infec- tions caused by multidrug-resistant (MDR) gram-negative pathogens that may cause pneumonia/ventilator-associated pneumonia (VAP), bac- teremia, meningitis, urinary tract infections, and central venous cathe- ter-related infections has been on the increase worldwide in the past 10 years [2,3]. For this reason, old antibiotics, such as polymyxin E (colistin) or polymyxin B, have come back [4]. There have been many clinical re- ports on the successful use of colistin or polymyxin B against infections caused by MDR Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumonia strains. Studies investigating the minimum inhibitory concentrations (MICs) of polymyxins against these MDR pathogens indi- cate their activity. Emergence of intensive care unit–acquired infections caused by multidrug-resistant gram-negative pathogens The emergence and rapid spread of MDR isolates, including P aerugi- nosa, A baumannii, K pneumoniae, and Enterobacter that cause ICU or * Corresponding author.
    [Show full text]
  • Antibacterial Prodrugs to Overcome Bacterial Resistance
    molecules Review Antibacterial Prodrugs to Overcome Bacterial Resistance Buthaina Jubeh , Zeinab Breijyeh and Rafik Karaman * Pharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem P.O. Box 20002, Palestine; [email protected] (B.J.); [email protected] (Z.B.) * Correspondence: [email protected] or rkaraman@staff.alquds.edu Academic Editor: Helen Osborn Received: 10 March 2020; Accepted: 26 March 2020; Published: 28 March 2020 Abstract: Bacterial resistance to present antibiotics is emerging at a high pace that makes the development of new treatments a must. At the same time, the development of novel antibiotics for resistant bacteria is a slow-paced process. Amid the massive need for new drug treatments to combat resistance, time and effort preserving approaches, like the prodrug approach, are most needed. Prodrugs are pharmacologically inactive entities of active drugs that undergo biotransformation before eliciting their pharmacological effects. A prodrug strategy can be used to revive drugs discarded due to a lack of appropriate pharmacokinetic and drug-like properties, or high host toxicity. A special advantage of the use of the prodrug approach in the era of bacterial resistance is targeting resistant bacteria by developing prodrugs that require bacterium-specific enzymes to release the active drug. In this article, we review the up-to-date implementation of prodrugs to develop medications that are active against drug-resistant bacteria. Keywords: prodrugs; biotransformation; targeting; β-lactam antibiotics; β-lactamases; pathogens; resistance 1. Introduction Nowadays, the issue of pathogens resistant to drugs and the urgent need for new compounds that are capable of eradicating these pathogens are well known and understood.
    [Show full text]